| Literature DB >> 29594229 |
Kaixian Yu1, Youyi Zhang1, Yang Yu2, Chao Huang3, Rongjie Liu1, Tengfei Li1, Liuqing Yang2, Jeffrey S Morris1, Veerabhadran Baladandayuthapani1, Hongtu Zhu1.
Abstract
Human Papilloma Virus (HPV) has been associated with oropharyngeal cancer prognosis. Traditionally the HPV status is tested through invasive lab test. Recently, the rapid development of statistical image analysis techniques has enabled precise quantitative analysis of medical images. The quantitative analysis of Computed Tomography (CT) provides a non-invasive way to assess HPV status for oropharynx cancer patients. We designed a statistical radiomics approach analyzing CT images to predict HPV status. Various radiomics features were extracted from CT scans, and analyzed using statistical feature selection and prediction methods. Our approach ranked the highest in the 2016 Medical Image Computing and Computer Assisted Intervention (MICCAI) grand challenge: Oropharynx Cancer (OPC) Radiomics Challenge, Human Papilloma Virus (HPV) Status Prediction. Further analysis on the most relevant radiomic features distinguishing HPV positive and negative subjects suggested that HPV positive patients usually have smaller and simpler tumors.Entities:
Keywords: CT image; HPV status; Oropharynx cancer; Radiomics; Statistical method
Year: 2017 PMID: 29594229 PMCID: PMC5862639 DOI: 10.1016/j.ctro.2017.10.001
Source DB: PubMed Journal: Clin Transl Radiat Oncol ISSN: 2405-6308
Fig. 1The overall procedure of the wining method.
Fig. 2The creation of consensus ROI out of a subject with 3 ROIs.
Final logistic regression.
| Variable | Estimated odds ratio | 95 | |
|---|---|---|---|
| 0.926 | [0.895, 0.958] | <0.0001 | |
| 2.045 | [1.833, 2.280] | <0.0001 |
Fig. 3The testing ROC curves of each fold of the 10-random-split of the training cohort.
Fig. 4Features comparison between HPV+ and HPV− subjects. A. HPV+ patients have a relatively smaller meanBreadth comparing to HPV− patients. B. Similarly, HPV− subjects have larger SphericalDisproportion than the HPV+ subjects.